Skip to Main Content

Paper Details

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Oncologist
57
2020
Author NameAffiliation
Aditya BardiaMassachusetts General Hospital Cancer Center Harvard Medical School
Jordi RodonVall D'Hebron Institute of Oncology
Martijn P LolkemaUniversity Medical Center Utrecht
Philippe L BedardPrincess Margaret Cancer Centre, University of Toronto
  • 1 - 4

Datasets

Release 1.2